Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1800/000104746917000744/a2230875z10-k.htm
SEC Filings
ABT Annual Reports
ABT Quarterly Reports
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report October 2019
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report October 2019
ABT Corporate News
Vote of Security Holders May 2023
Earnings Release
Financial Exhibit April 2023
Bylaw Change
Financial Exhibit February 2023
Earnings Release
Financial Exhibit January 2023
Bylaw Change
Financial Exhibit December 2022
Event for Officers October 2022
Earnings Release
Financial Exhibit October 2022
Bylaw Change
Event for Officers
Financial Exhibit September 2022
Earnings Release
Financial Exhibit July 2022
Vote of Security Holders May 2022
Vote of Security Holders
May 2023
Earnings Release
Financial Exhibit
Financial Exhibit
April 2023
Bylaw Change
Financial Exhibit
Financial Exhibit
February 2023
Earnings Release
Financial Exhibit
Financial Exhibit
January 2023
Bylaw Change
Financial Exhibit
Financial Exhibit
December 2022
Event for Officers
October 2022
Earnings Release
Financial Exhibit
Financial Exhibit
October 2022
Bylaw Change
Event for Officers
Financial Exhibit
Event for Officers
Financial Exhibit
September 2022
Earnings Release
Financial Exhibit
Financial Exhibit
July 2022
Vote of Security Holders
May 2022
Last10K.com | 10-K Annual Report Fri Feb 17 2017
Exhibit 99.1
Abbott Laboratories
Cardiovascular and Neuromodulation
2016 Comparable Sales*
(unaudited)
|
|
|
2016 Sales ($ in millions) |
| ||||||||
|
Worldwide |
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management and Heart Failure |
|
1,021 |
|
1,089 |
|
1,034 |
|
988 |
|
4,132 |
|
|
Cardiovascular and Structural Heart |
|
921 |
|
1,037 |
|
958 |
|
981 |
|
3,897 |
|
|
Neuromodulation |
|
116 |
|
140 |
|
141 |
|
167 |
|
564 |
|
|
Total Cardiovascular and Neuromodulation |
|
2,058 |
|
2,266 |
|
2,133 |
|
2,136 |
|
8,593 |
|
|
|
|
2016 Sales ($ in millions) |
| ||||||||
|
U.S. |
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management and Heart Failure |
|
570 |
|
574 |
|
551 |
|
488 |
|
2,183 |
|
|
Cardiovascular and Structural Heart |
|
368 |
|
427 |
|
390 |
|
388 |
|
1,573 |
|
|
Neuromodulation |
|
84 |
|
97 |
|
106 |
|
127 |
|
414 |
|
|
Total Cardiovascular and Neuromodulation |
|
1,022 |
|
1,098 |
|
1,047 |
|
1,003 |
|
4,170 |
|
|
|
|
2016 Sales ($ in millions) |
| ||||||||
|
International |
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management and Heart Failure |
|
451 |
|
515 |
|
483 |
|
500 |
|
1,949 |
|
|
Cardiovascular and Structural Heart |
|
553 |
|
610 |
|
568 |
|
593 |
|
2,324 |
|
|
Neuromodulation |
|
32 |
|
43 |
|
35 |
|
40 |
|
150 |
|
|
Total Cardiovascular and Neuromodulation |
|
1,036 |
|
1,168 |
|
1,086 |
|
1,133 |
|
4,423 |
|
The following information was filed by Abbott Laboratories (ABT) on Wednesday, January 25, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Abbott Laboratories's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abbott Laboratories.
Assess how Abbott Laboratories's management team is paid from their Annual Proxy
Abbott Laboratories's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheet
Consolidated Balance Sheet (parenthetical)
Consolidated Statement Of Cash Flows
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parenthetical)
Consolidated Statement Of Earnings
Consolidated Statement Of Shareholders' Investment
Consolidated Statement Of Shareholders' Investment (parenthetical)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (details)
Accumulated Other Comprehensive Income (tables)
Assets And Liabilities Held For Disposition
Assets And Liabilities Held For Disposition (details)
Assets And Liabilities Held For Disposition (tables)
Business Acquisitions
Business Acquisitions (tables)
Business Acquisitions - Alere (details)
Business Acquisitions - Cfr (details)
Business Acquisitions - St. Jude Medical (details)
Business Acquisitions - Tendyne (details)
Business Acquisitions - Topera (details)
Business Acquisitions - Veropharm (details)
Debt And Lines Of Credit
Debt And Lines Of Credit (details)
Debt And Lines Of Credit (tables)
Discontinued Operations
Discontinued Operations (tables)
Discontinued Operations - By Disposal (details)
Discontinued Operations - Summary (details)
Financial Instruments, Derivatives And Fair Value Measures
Financial Instruments, Derivatives And Fair Value Measures (tables)
Financial Instruments, Derivatives And Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (details)
Financial Instruments, Derivatives And Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (details)
Financial Instruments, Derivatives And Fair Value Measures - Derivative Information (details)
Financial Instruments, Derivatives And Fair Value Measures - Derivative Instruments, Gain (loss) (details)
Goodwill And Intangible Assets
Goodwill And Intangible Assets - Goodwill (details)
Goodwill And Intangible Assets - Intangible Assets (details)
Incentive Stock Program
Incentive Stock Program (details)
Incentive Stock Program (tables)
Litigation And Environmental Matters
Litigation And Environmental Matters (details)
Post-employment Benefits
Post-employment Benefits (tables)
Post-employment Benefits - General (details)
Post-employment Benefits - Net Asset Value (details)
Post-employment Benefits - Plan Assets (details)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (details)
Quarterly Results (unaudited) (tables)
Restructuring Plans
Restructuring Plans (details)
Restructuring Plans (tables)
Schedule Ii Valuation And Qualifying Accounts
Schedule Ii Valuation And Qualifying Accounts (details)
Segment And Geographic Area Information
Segment And Geographic Area Information (tables)
Segment And Geographic Area Information - Geographic Information (details)
Segment And Geographical Area Information - General (details)
Segment And Geographical Area Information - Reconciliation (details)
Subsequent Event
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Concentration Of Risk And Guarantees (details)
Summary Of Significant Accounting Policies - General (details)
Summary Of Significant Accounting Policies - Property And Equipment (details)
Supplemental Financial Information
Supplemental Financial Information (tables)
Supplemental Financial Information - Foreign Currency (details)
Supplemental Financial Information - Investments (details)
Supplemental Financial Information - Other Accrued Liabilities (details)
Supplemental Financial Information - Other Income And Expense (details)
Supplemental Financial Information - Post-employment Obligations And Other Long-term Liabilities (details)
Taxes On Earnings From Continuing Operations
Taxes On Earnings From Continuing Operations (tables)
Taxes On Earnings From Continuing Operations - General (details)
Taxes On Earnings From Continuing Operations - Settlements (details)
Material Contracts, Statements, Certifications & more
Abbott Laboratories provided additional information to their SEC Filing as exhibits
Exhibit 4.22: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.10: Material Contract
Exhibit 10.49: Material Contract
Exhibit 10.59: Material Contract
Exhibit 10.60: Material Contract
Exhibit 10.61: Material Contract
Exhibit 10.62: Material Contract
Exhibit 12: Statement Regarding Calculation Of Ratios
Exhibit 21: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: ABT
CIK: 1800
Form Type: 10-K Annual Report
Accession Number: 0001047469-17-000744
Submitted to the SEC: Fri Feb 17 2017 4:17:24 PM EST
Accepted by the SEC: Fri Feb 17 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/abt/0001047469-17-000744.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...